Quell Therapeutics Ltd has made two new appointments to its board and announced a new senior vice president for research and translation. Dhaval Patel and Sir Robert Lechler have joined the board of the company, which develops engineered T regulatory cell therapies. Dr Patel is currently chief scientific officer at the Belgian biopharmaceutical company UCB SA.
Professor Lechler is currently provost and senior vice-president (health) at King’s College London. He is also executive director of King’s Health Partners, and president of the Academy of Medical Sciences. His academic work has focused on clinical transplantation tolerance. Natalie Belmonte also joins Quell as senior vice president for research and translation. She has more than 15 years of experience working in the field of cell therapy in both academic and biotech environments and specifically has experience with the development of Treg cell therapies.
Quell Therapeutics announced the appointments on 11 June 2020.
Copyright 2020 Evernow Publishing Ltd